CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial [0.03%]
纳瓦司星联合派姆单抗治疗选定的晚期实体瘤：一项二期随机试验
Andrew J Armstrong,Ravit Geva,Hyun Cheol Chung et al.
Andrew J Armstrong et al.
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit of CXCR2 inhibition in multiple solid tumor...
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer [0.03%]
日本广泛期小细胞肺癌患者接受pembrolizumab联合化疗的Ⅰ期研究
Naoyuki Nogami,Takaaki Tokito,Yoshitaka Zenke et al.
Naoyuki Nogami et al.
Background: Part E of the KEYNOTE-011 (NCT01840579) study assessed the safety and antitumor activity of pembrolizumab plus platinum-etoposide chemotherapy in Japanese patients with previously untreated extensive-stage sma...
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort [0.03%]
navitoclax和sorafenib用于治疗复发或难治性实体瘤的1期临床试验附加肝细胞癌队列研究
Oluwadunni E Emiloju,Jun Yin,Emily Koubek et al.
Oluwadunni E Emiloju et al.
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival BCL2 proteins, resulting in apoptosis. Sorafenib, an oral multi kinase inhibitor also promotes apoptosis and inhibits tumor angiogenesis. ...
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis [0.03%]
尼伏单抗诱发心肌炎的临床特点，诊断和治疗管理
Meng-Ting Li,Yang He,Si-Yong Huang et al.
Meng-Ting Li et al.
Nivolumab can cause fatal myocarditis. We aimed to analyze the clinical characteristics of nivolumab-induced myocarditis and provide evidence for clinical diagnosis, treatment, and prevention. Studies involving nivolumab-induced myocarditis...
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function [0.03%]
靶向HER2和CLDN18.2的双特异性抗体通过增强免疫效应功能消除表达双抗原的胃癌细胞
Jingying Yue,Shuai Shao,Jie Zhou et al.
Jingying Yue et al.
Gastric cancer (GC) is widely regarded as one of the toughest cancers to treat. Trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2) for GC treatment, has demonstrated clinical success. However, these patients have...
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells [0.03%]
乳腺癌细胞中SLC7A5转运蛋白的靶向递送脂质体Ribociclib
Mahtab Afsharzadeh,Jaleh Varshosaz,Mina Mirian et al.
Mahtab Afsharzadeh et al.
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analy...
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects [0.03%]
食物和种族对健康韩国男性、高加索男性和中国男性中新一代聚ADP核糖聚合酶抑制剂veliparib药代动力学影响的研究
Hyun Chul Kim,Eunsol Yang,Soyoung Lee et al.
Hyun Chul Kim et al.
Aim: Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and s...
Randomized Controlled Trial
Investigational new drugs. 2024 Feb;42(1):80-88. DOI:10.1007/s10637-023-01405-z 2024
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage [0.03%]
艾日布林和菲莫匹诺斯特联合用药通过增强DNA损伤诱导对急性髓系白血病细胞的协同作用
Yue Wang,Xingyu Lin,Yue Wang et al.
Yue Wang et al.
In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukemia (AML). However, there is still ample opportunity for enhancing efficacy. The Wee1 inhibitor adavosertib (ADA) shows...
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma [0.03%]
RPTOR突变是黑色素瘤免疫治疗有效的新型预测因子
Yanfang Jiang,Xintong Hu,Zhouyu Wang et al.
Yanfang Jiang et al.
Identifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors (ICIs) is crucial. Regulatory Associated Protein of MTOR Complex 1 (RPTOR), one of the genes in the mTOR pathway, plays a role in regulating tumor pro...
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis [0.03%]
纳武单抗诱导的胃炎的临床特征、诊断、治疗及预后
Haibo Lei,Wei Sun,Xiang Liu et al.
Haibo Lei et al.
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induced gastritis remain unclear. To explore the clinical characteristics of nivolumab induced gastritis, and to provide ref...